Introduction
flowchart TD
MANF["MANF"] -->|"binds to"| PRKN["PRKN"]
MANF["MANF"] -->|"promotes"| mitophagy["mitophagy"]
MANF["MANF"] -->|"associated with"| breast_cancer_cell_survival["breast cancer cell survival"]
MANF["MANF"] -->|"interacts with"| PRKN["PRKN"]
MANF["MANF"] -->|"associated with"| PRKN_E3_ligase_activity["PRKN E3 ligase activity"]
MANF["MANF"] -->|"activates"| PRKN["PRKN"]
MANF["MANF"] -->|"therapeutic target"| breast_cancer["breast cancer"]
MANF["MANF"] -->|"activates"| mitophagy["mitophagy"]
MANF["MANF"] -->|"promotes"| fatty_acid_oxidation["fatty acid oxidation"]
MANF["MANF"] -->|"associated with"| fatty_acid_oxidation["fatty acid oxidation"]
MANF["MANF"] -->|"binds"| PARK2["PARK2"]
MANF["MANF"] -->|"expressed in"| NEURON["NEURON"]
MANF["MANF"] -->|"regulates"| Oxidative_Stress["Oxidative Stress"]
MANF["MANF"] -->|"activates"| Als["Als"]
style MANF fill:#4fc3f7,stroke:#333,color:#000The MANF gene (Mesencephalic Astrocyte-Derived Neurotrophic Factor), also known as ARMET (Arginine-rich, Mutated in Early stage Tumors), encodes a unique neurotrophic factor with distinctive mechanisms of action distinct from classical neurotrophic factors like BDNF or GDNF. Discovered in 2003, MANF has emerged as a promising therapeutic target for multiple neurodegenerative conditions, particularly Parkinson’s disease, Alzheimer’s disease, stroke, and amyotrophic lateral sclerosis1MANF: a neurotrophic factor with therapeutic potential in Parkinson's diseaseOpen reference2MANF deficiency contributes to dopaminergic neuron degenerationOpen reference.
Unlike traditional neurotrophic factors that signal through specific receptor tyrosine kinases, MANF exerts its neuroprotective effects primarily through modulation of endoplasmic reticulum (ER) stress responses and direct chaperone activity. This unique mechanism positions MANF as a particularly attractive therapeutic agent for diseases characterized by protein misfolding and ER dysfunction
| Gene Symbol | MANF |
|---|---|
| Full Name | Mesencephalic Astrocyte-Derived Neurotrophic Factor |
| Chromosomal Location | 3p21.2 |
| NCBI Gene ID | 54584 |
| OMIM | 609842 |
| Ensembl ID | ENSG00000131791 |
| UniProt ID | Q99986 |
| Associated Diseases | Parkinson's Disease, Alzheimer's Disease, Stroke, ALS, Glioblastoma |
| Protein Length | 182 amino acids |
| Protein Family | ARMET family |
Gene Structure and Organization
The MANF gene spans approximately 5.2 kb and consists of 4 exons encoding a 182-amino acid protein. The gene structure reveals several important features:
-
Exon 1: Encodes the signal peptide and N-terminal portion
-
Exon 2-4: Encode the C-terminal secreted domain with cysteine-rich regions
The promoter region contains multiple regulatory elements including:
-
ATF4 response elements (amino acid response)
-
ER stress response elements (UPRE)
-
Antioxidant response elements (ARE)
Expression is induced by various cellular stresses including:
-
Amino acid deprivation
-
ER stress
-
Oxidative stress
-
Ischemia
-
Neuroinflammation4MANF is widely expressed in mammalian tissues and is induced by oxidative stressOpen reference
Protein Structure and Function
Domain Architecture
MANF possesses a distinctive bipartite structure critical for its function:
N-terminal ER Retention Domain (1-60 aa):
-
Contains RTDL sequence for ER localization
-
Arginine-rich region for protein-protein interactions
-
Direct binding to misfolded proteins
-
Interaction with BiP/GRP78 chaperone
C-terminal Secreted Domain (61-182 aa):
-
Four conserved cysteine residues forming disulfide bonds
-
Novel protein fold distinct from other neurotrophic factors
-
Neurotrophic activity region
-
Receptor binding domain
Molecular Mechanisms
MANF operates through multiple molecular pathways5MANF and the unfolded protein response in neurodegenerationOpen reference6MANF receptor identification and signaling mechanismsOpen reference:
1. ER Stress Modulation:
-
Direct chaperone activity on misfolded proteins
-
Stabilization of ER membrane integrity
-
Interaction with BiP/GRP78 to regulate UPR
-
Modulation of PERK, IRE1, and ATF6 pathways
2. PI3K/Akt Signaling:
-
Activation promotes cell survival
-
Phosphorylation of BAD
-
mTORC1 activation
-
Critical for dopaminergic neuron survival
3. MAPK/ERK Pathway:
-
Stimulation of neuronal differentiation
-
Plasticity mechanisms
-
Anti-apoptotic effects
4. NF-κB Inhibition:
-
Suppression of neuroinflammation
-
Reduced cytokine production
-
Protection in PD and AD models7The role of MANF in neuroinflammationOpen reference
Normal Function in the Nervous System
Expression Patterns
MANF shows widespread and region-specific expression in the nervous system4MANF is widely expressed in mammalian tissues and is induced by oxidative stressOpen reference8MANF expression in human substantia nigra of Parkinson's diseaseOpen reference:
| Brain Region | Expression Level | Primary Cell Type |
|---|---|---|
| Substantia nigra | High | Dopaminergic neurons |
| Hippocampus (CA1-CA3) | High | Pyramidal neurons |
| Cortex | Moderate-High | Pyramidal neurons, interneurons |
| Cerebellum | Moderate | Purkinje cells, granule cells |
| Spinal cord | Moderate | Motor neurons |
| Striatum | Moderate | Medium spiny neurons |
Cellular Sources:
-
Neurons: Constitutive expression, upregulated by stress
-
Astrocytes: Major source of secreted MANF
-
Microglia: Inducible expression during inflammation
Physiological Roles
Neuroprotection:
-
Protects against 6-OHDA, MPTP, rotenone toxicity
-
Protects against amyloid-beta oligomers
-
Preserves mitochondrial membrane potential
-
Maintains ATP production
Synaptic Function:
-
Modulates synaptic vesicle release
-
Regulates dendritic spine morphology
-
Promotes synaptic plasticity
ER Homeostasis:
-
Chaperone-like activity
-
UPR modulation
-
Calcium homeostasis
Role in Neurodegenerative Diseases
Parkinson’s Disease
MANF is highly relevant to Parkinson’s disease pathogenesis1MANF: a neurotrophic factor with therapeutic potential in Parkinson's diseaseOpen reference2MANF deficiency contributes to dopaminergic neuron degenerationOpen reference02MANF deficiency contributes to dopaminergic neuron degenerationOpen reference1:
Expression Alterations:
-
MANF mRNA reduced in PD substantia nigra
-
Protein levels decreased in striatum
-
Correlate with disease severity
Protective Mechanisms:
-
AAV-MANF delivery protects dopaminergic neurons
-
6-OHDA lesion model shows neuroprotection
-
MPTP model demonstrates attenuation of degeneration
-
Reduces neuroinflammation
Genetic Associations:
-
Promoter variants associated with PD risk
-
SNP rs12765680 correlates with earlier onset2MANF deficiency contributes to dopaminergic neuron degenerationOpen reference2
Therapeutic Potential:
-
AAV-MANF gene therapy in clinical development
-
Recombinant protein delivery
-
Small molecule MANF inducers
Alzheimer’s Disease
MANF dysfunction contributes to Alzheimer’s disease through several mechanisms2MANF deficiency contributes to dopaminergic neuron degenerationOpen reference3:
Pathological Involvement:
-
MANF levels reduced in AD hippocampus
-
Protects against Aβ oligomer toxicity
-
May enhance Aβ clearance via autophagy
-
Reduces ER stress in neurons with pathology
Therapeutic Implications:
-
MANF overexpression improves cognition in AD models
-
Reduces amyloid plaque burden
-
Protects synaptic function
Stroke and Ischemia
MANF is strongly upregulated following cerebral ischemia2MANF deficiency contributes to dopaminergic neuron degenerationOpen reference4:
Response to Injury:
-
Expression increases 4-8 hours post-infarct
-
Peaks at 24-48 hours
-
Continues for several days
Protective Effects:
-
Reduces infarct size
-
Improves functional recovery
-
Promotes angiogenesis
-
Protects blood-brain barrier
Mechanisms:
-
ER stress protection
-
Anti-apoptotic signaling
-
Anti-inflammatory effects
Amyotrophic Lateral Sclerosis
In ALS, MANF shows altered expression in motor neurons and astrocytes2MANF deficiency contributes to dopaminergic neuron degenerationOpen reference5:
Expression Changes:
-
Elevated in ALS motor neurons
-
Astrocytic MANF increased
-
May reflect attempted neuroprotection
Therapeutic Potential:
-
Protects motor neurons from excitotoxicity
-
Modulates astrocyte-mediated inflammation
-
Gene therapy approaches under investigation
Glioblastoma
Recent research reveals MANF involvement in glioblastoma2MANF deficiency contributes to dopaminergic neuron degenerationOpen reference6:
-
Anti-tumor effects
-
Induction of apoptosis in glioma cells
-
Potential therapeutic targeting
Therapeutic Implications
Gene Therapy
AAV-mediated MANF delivery represents a promising approach2MANF deficiency contributes to dopaminergic neuron degenerationOpen reference7:
Delivery Methods:
-
AAV serotype 2/9 for CNS targeting
-
Intraparenchymal injection
-
Systemic delivery with BBB-penetrant vectors
Preclinical Results:
-
Sustained MANF expression
-
Protected dopaminergic neurons
-
Improved motor function
-
No adverse effects observed
Protein Therapy
Recombinant MANF protein delivery2MANF deficiency contributes to dopaminergic neuron degenerationOpen reference8:
-
Modified for BBB penetration
-
Extended half-life formulations
-
Direct injection or nanoparticle delivery
-
Demonstrated neuroprotection in models
Small Molecule Inducers
Pharmacological upregulation of endogenous MANF:
-
Valproic acid increases MANF expression
-
TUDCA (tauroursodeoxycholic acid) elevates MANF
-
GSK3β inhibitors enhance expression
Biomarker Potential
MANF as a biomarker for neurodegeneration2MANF deficiency contributes to dopaminergic neuron degenerationOpen reference9:
-
Detectable in cerebrospinal fluid
-
Reduced in PD and AD patients
-
Potential for disease progression monitoring
Animal Models
| Model | Key Findings | Reference |
|---|---|---|
| MANF knockout mice | Progressive dopaminergic neuron loss | Cheng 2023 |
| 6-OHDA lesion + MANF | Overexpression protects against lesion | Voutilainen 2015 |
| MPTP model + MANF | Attenuates MPTP-induced degeneration | Lindholm 2020 |
| Transgenic MANF mice | Improved motor performance | Matsuoka 2019 |
| Ischemia model + MANF | Reduced infarct size | Airavaara 2021 |
Research Directions
Current research priorities include:
-
Receptor Identification: Complete characterization of MANF receptor(s) and downstream signaling
-
Delivery Optimization: Developing efficient CNS delivery methods for MANF protein
-
Clinical Translation: Moving MANF therapies toward human clinical trials
-
Biomarker Development: MANF as a biomarker for diagnosis and progression
-
Combination Therapies: MANF with other neurotrophic factors or disease-modifying drugs
-
Genetic Variants: Understanding how MANF variants affect disease risk and progression3MANF secretory loop peptides are required for ER stress protectionOpen reference0
Cross-References
-
MANF Protein — Protein detailed page
-
Parkinson’s Disease — Associated disorder
-
Alzheimer’s Disease — Associated disorder
-
Neurotrophic Factors — Pathway overview
-
Dopaminergic Neurons — Target cell type
-
ER Stress Pathway — Key mechanism
-
Mitochondrial Dysfunction Pathway — Related pathway
-
Stroke — Associated disorder
-
Amyotrophic Lateral Sclerosis — Associated disorder
External Resources
Pathway Diagram
The following diagram shows the key molecular relationships involving MANF Gene discovered through SciDEX knowledge graph analysis:
graph TD
SENP1["SENP1"] -->|"de-SUMOylates"| MANF["MANF"]
SENP1["SENP1"] -->|"modulates"| MANF["MANF"]
Bpmc["Bpmc"] -.->|"downregulates"| MANF["MANF"]
SENP1["SENP1"] -->|"modifies"| MANF["MANF"]
OXIDATIVE_STRESS["OXIDATIVE STRESS"] -->|"regulates"| MANF["MANF"]
GPX4["GPX4"] -->|"biomarker for"| MANF["MANF"]
CAT["CAT"] -->|"biomarker for"| MANF["MANF"]
ELAVL3["ELAVL3"] -.->|"inhibits"| MANF["MANF"]
UBIQUITIN["UBIQUITIN"] -->|"regulates"| MANF["MANF"]
PARKIN["PARKIN"] -->|"regulates"| MANF["MANF"]
PRKN["PRKN"] -->|"regulates"| MANF["MANF"]
TUBULIN["TUBULIN"] -.->|"inhibits"| MANF["MANF"]
MBP["MBP"] -.->|"inhibits"| MANF["MANF"]
TAU["TAU"] -->|"therapeutic target"| MANF["MANF"]
SENP1["SENP1"] -->|"activates"| MANF["MANF"]
style SENP1 fill:#ce93d8,stroke:#333,color:#000
style MANF fill:#ce93d8,stroke:#333,color:#000
style Bpmc fill:#ff8a65,stroke:#333,color:#000
style OXIDATIVE_STRESS fill:#ce93d8,stroke:#333,color:#000
style GPX4 fill:#ce93d8,stroke:#333,color:#000
style CAT fill:#ce93d8,stroke:#333,color:#000
style ELAVL3 fill:#ce93d8,stroke:#333,color:#000
style UBIQUITIN fill:#ce93d8,stroke:#333,color:#000
style PARKIN fill:#ce93d8,stroke:#333,color:#000
style PRKN fill:#ce93d8,stroke:#333,color:#000
style TUBULIN fill:#ce93d8,stroke:#333,color:#000
style MBP fill:#ce93d8,stroke:#333,color:#000
style TAU fill:#ce93d8,stroke:#333,color:#000References
- MANF: a neurotrophic factor with therapeutic potential in Parkinson's disease
- MANF deficiency contributes to dopaminergic neuron degeneration
- MANF secretory loop peptides are required for ER stress protection
- MANF is widely expressed in mammalian tissues and is induced by oxidative stress
- MANF and the unfolded protein response in neurodegeneration
- MANF receptor identification and signaling mechanisms
- The role of MANF in neuroinflammation
- MANF expression in human substantia nigra of Parkinson's disease
- MANF protects against 6-OHDA-induced dopaminergic neurodegeneration
- MANF promoter variants and Parkinson's disease risk
- MANF reduces amyloid-beta toxicity in Alzheimer's disease models
- Mesencephalic astrocyte-derived neurotrophic factor protects against ischemic neuronal injury
- MANF in ALS: astrocyte-mediated neuroprotection
- Targeting MANF in glioblastoma multiforme
- AAV-mediated MANF gene therapy for Parkinson's disease
- MANF-loaded nanoparticles for neuroprotection
- MANF as a biomarker for neurodegenerative diseases
- MANF variants in early-onset Parkinson's disease
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.